Inactive Instrument

Press Releases Bellerophon Therapeutics LLC Nasdaq

Equities

End-of-day quote Nasdaq Other stock markets
-	-

May. 02	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 25	North American Morning Briefing : More Tech -2-	DJ

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Bellerophon Therapeutics : Costs Associated with Exit/Disposal - Form 8-K	23-06-29	PU
Bellerophon Therapeutics : Conference Call Presentation	23-06-05	PU
Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease	23-06-05	AQ
Bellerophon Therapeutics : Corporate Presentation	23-05-21	PU
BELLEROPHON THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	23-05-15	AQ
Bellerophon Therapeutics: Q1 Earnings Snapshot	23-05-15	AQ
Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results	23-05-15	AQ
Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse in Fibrotic Interstitial Lung Disease	23-05-12	AQ
BELLEROPHON THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	23-05-11	AQ
BELLEROPHON THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-05-11	AQ
Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease	23-05-11	AQ
BELLEROPHON THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	23-05-05	AQ
BELLEROPHON THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	23-04-25	AQ
BELLEROPHON THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-31	AQ
Bellerophon Therapeutics : Strengthened Balance Sheet Through $5 Million Registered Direct Offering with Life Sciences-focused Institutional Investor - Form 8-K	23-03-31	PU
Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results	23-03-31	AQ
Bellerophon Therapeutics : Material Agreement - Form 8-K	23-03-06	PU
BELLEROPHON THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	23-03-06	AQ
Bellerophon Therapeutics Announces $5 Million Registered Direct Offering	23-03-06	AQ
BELLEROPHON THERAPEUTICS, INC. : Other Events (form 8-K)	23-03-03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Bellerophon Therapeutics LLC Nasdaq

Equities

Press Releases

Filters